GHRP-6
GHRP-6 scored 4.4 / 10 (⚠️ Caution) on the BioHarmony scale as a Substance → Peptide → Growth / Repair Peptide.
GHRP-6 is a synthetic peptide that activates the ghrelin receptor to release a pulse of your own growth hormone. It is historically pivotal but the least selective common option, with the heaviest appetite, cortisol, and prolactin effects, and no human outcome trial for body composition, per Cabrales 2013 and Locke 1995.
What is GHRP-6?
GHRP-6, short for Growth Hormone Releasing Peptide-6, is a lab-made six-amino-acid peptide that nudges your own pituitary to release a short pulse of growth hormone. It does this by activating the ghrelin receptor, the same receptor your stomach hormone ghrelin uses, which sits on the pituitary and in the brain. It is one of the original peptides in this family, and that history is its biggest claim to importance. GHRP-6 was the research tool scientists used to clone that receptor, per Howard 1996, and that work led them straight to the discovery of ghrelin itself, per Kojima 1999. In other words, a synthetic peptide reverse-engineered an entire hormone system.
Here is the catch, and it is the reason the score lands in caution. For the goal people actually buy it for, raising growth hormone to improve body composition, there are no human outcome trials. The human evidence is the acute growth-hormone response and diagnostic testing, per Bowers 1990, not fat loss or muscle gain. On top of that, GHRP-6 is the least selective of the common peptides in this group. It comes with the heaviest appetite stimulation, plus cortisol, prolactin, and water retention. There is a real preclinical heart-protection research story, but that is a different use and animal data, so it does not raise the body-composition case. Newer selective options do the same growth-hormone job with far fewer side effects, which is exactly why caution is the right call.
Terminology
A few terms decide how you read this report, because the gap between "growth hormone goes up" and "the outcome is proven" is where GHRP-6 lives, and because the off-target hormones are the whole side-effect story. Getting these straight is what separates a fair read of GHRP-6 from the hype around it. Most of the confusion in this space comes from treating "raised a hormone" and "changed your body" as the same thing, when they are not. GHRP-6 clearly does the first in people. Nothing shows it does the second. The other recurring trap is lumping all the peptides in this family together as if they behave the same, when selectivity, the cleanliness of the growth-hormone signal, is exactly what separates GHRP-6 from the newer options most people now run. Keep these definitions in mind and the rest of the report reads as a straight cost-benefit call rather than a marketing pitch.
- GHRP: Growth-hormone-releasing peptide. A class of synthetic peptides that trigger a growth-hormone pulse by acting on the ghrelin receptor. GHRP-6 is the oldest common member.
- GHS-R1a: The growth hormone secretagogue receptor, better known as the ghrelin receptor. The target GHRP-6 activates to release growth hormone and to stimulate appetite.
- Ghrelin: The natural stomach hormone that drives hunger and growth-hormone release. GHRP-6 mimics it, which is why hunger is the signature effect.
- GHRH: Growth-hormone-releasing hormone. A separate natural signal. GHRP-6 is usually stacked with a GHRH peptide because the two work together for a bigger pulse.
- IGF-1: Insulin-like growth factor 1. The downstream signal growth hormone produces, the marker users track, and the pathway behind the cancer concern.
- Selectivity: How cleanly a peptide raises growth hormone without also raising cortisol, ACTH, and prolactin. GHRP-6 is the least selective common option.
- Orexigenic: Appetite-stimulating. GHRP-6 is strongly orexigenic, and that effect is separate from its growth-hormone effect.
- Ipamorelin: A newer, selective peptide in the same family that raises growth hormone with much less appetite and cortisol effect. It has its own scorecard.
How do you take GHRP-6?
Dosing & Protocols
Dosing information is summarized from published research and community reports. This is not a prescribing guide. Consult a healthcare provider before starting any protocol.
View 1 route and 4 protocols
Routes & Forms
| Route | Form | Clinical Range | Community Range |
|---|---|---|---|
| Subcutaneous injection | Lyophilized powder reconstituted with bacteriostatic water | No approved clinical dose | 100 to 300 mcg per dose, 1 to 3 times daily |
Protocols
Conservative starter Anecdotal
- Dose
- 100 mcg
- Frequency
- Once daily, pre-sleep
- Duration
- 8 to 12 weeks
Pre-sleep and fasted, to ride the natural overnight growth-hormone pulse and gauge the appetite effect before scaling up.
Standard with a GHRH peptide Anecdotal
- Dose
- 100 to 200 mcg of each
- Frequency
- 1 to 2 times daily
- Duration
- 8 to 12 weeks
Stacked with a GHRH peptide such as CJC-1295 no-DAC, often in one syringe, to exploit the documented GHRH plus GHRP synergy. The GHRH part raises the ceiling of the pulse.
Bulking-phase appetite assist Anecdotal
- Dose
- 100 to 300 mcg
- Frequency
- 2 to 3 times daily
- Duration
- 8 to 12 weeks
The one use case where the strong hunger is wanted, to help eat in a surplus. Counterproductive for any fat-loss goal.
Cycled protocol Anecdotal
- Dose
- 100 to 200 mcg
- Frequency
- 1 to 3 times daily
- Duration
- On and off blocks
Community practice cycles on and off to limit the desensitization seen with continuous exposure. There is no validated cycling schedule.
How this score is calculated →
What are the benefits of GHRP-6?
Upside contribution: 1.67
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Efficacy | 25% | 2.8 | 0.700 | |
| Breadth | 15% | 2.8 | 0.420 | |
| Evidence | 25% | 2.5 | 0.625 | |
| Speed | 10% | 3.0 | 0.300 | |
| Durability | 10% | 2.0 | 0.200 | |
| Bioindividuality | 15% | 2.8 | 0.420 | |
| Total | 2.665 |
Upside Rationale
The upside of GHRP-6 is concentrated in a real, fast mechanism and in its historical role, not in proven results. Its genuine asset is a reliable growth-hormone pulse in people, plus a strong synergy when stacked with a GHRH peptide, which together make it one of the most potent growth-hormone stimuli available for provocation. Its weakness is that none of this has been shown to produce fat loss, muscle gain, or any hard outcome in a human trial. Breadth and bioindividuality score moderately because the growth-hormone axis plausibly touches many systems and the response clearly varies by age and body fat. Evidence is held back by the absence of outcome trials, even though the acute pharmacology is well documented. The honest framing is that GHRP-6 has a strong upstream signal and a thin downstream record. Everything that scores well here is about what the peptide does to your hormones in the short term. Everything that scores poorly is about whether that translates into a change you would actually notice or measure, which no one has shown in a controlled study.
Efficacy (2.8/5.0): Efficacy is moderate because the growth-hormone rise is real and reproducible but its payoff for body composition is undemonstrated in people. GHRP-6 reliably raises growth hormone in normal men and acts synergistically with GHRH, per Bowers 1990, and the combined provocation is potent enough to be used diagnostically, per Haijma 2005. What is missing is any human trial showing fat loss, lean-mass gain, or strength change. The expectation of a body-composition benefit is an extrapolation from growth-hormone physiology, not from GHRP-6 outcome data. A confirmed hormone rise without a confirmed human outcome cannot score as strongly effective for the uses people care about, which is why this sits in the middle rather than higher.
Breadth of Benefits (2.8/5.0): Breadth is moderate because growth hormone plausibly influences many systems even though almost none are proven for GHRP-6. The growth-hormone axis touches body composition, sleep, recovery, skin, and bone in theory, and GHRP-6 raises pulsatile growth hormone during exposure, per Jaffe 1993. There is also a distinct preclinical research direction in the heart, where GHRP-6 shows cytoprotective effects through a second receptor, per Bodart 2002. The boundary is that breadth of mechanism is not breadth of proof. In people, none of these systems has a controlled GHRP-6 endpoint, and the heart work is animal and a different indication, so it does not count toward the growth-hormone-optimization case.
Evidence Quality (2.5/5.0): Evidence quality is the dimension that keeps the score in caution. The acute human pharmacology is genuinely solid: multiple in-man studies document the growth-hormone response and its GHRH synergy, per Leal-Cerro 1995, and a dedicated human pharmacokinetic study quantifies the short exposure, per Cabrales 2013. But there are zero human outcome trials for the scored use, and the cardioprotection literature is animal and cell work. So the score reflects strong mechanistic and diagnostic evidence sitting on top of an empty outcomes file. That is better than a peptide with no human data at all, but well short of anything outcome-proven, which is why it lands at the low-moderate mark.
Speed of Onset (3.0/5.0): Speed is a relative bright spot for GHRP-6. The growth-hormone rise happens within minutes of a subcutaneous dose, and the peptide has an elimination half-life of about 2.5 hours, per Cabrales 2013. Subjective effects appear fast too: hunger usually hits within about 20 to 60 minutes, and deeper sleep is reported within days of pre-bed dosing. The acute pharmacology is well supported. What is not fast, and not documented at all, is any body-composition change, which would take months and rests on physiology rather than trials. So the score rewards quick, reliable acute action while noting that the meaningful outcomes are slow and unproven.
Durability (2.0/5.0): Durability is low because the effect is transient and fades off the peptide. GHRP-6 raises growth-hormone pulse amplitude only while it is on board, per Jaffe 1993, and continuous exposure actually blunts the response to a later dose, per Huhn 1993. There is no documented lasting body-composition change after stopping, because no outcome trials exist to show otherwise. This is a stay-on-it tool, not a reset. The desensitization is also why people cycle on and off rather than dosing continuously, which adds friction and limits how durable any benefit can be.
Bioindividuality Upside (2.8/5.0): Response to GHRP-6 varies enough that some people notice clearly more than others. Older adults and those with more body fat tend to show a blunted growth-hormone response to provocation, per Haijma 2005, so age and adiposity are real modifiers. The appetite response also varies widely from person to person, and for some users the hunger is overwhelming while for others it is manageable. These are somewhat predictable modifiers, which lifts this above the floor, but they cut both ways: a meaningful share of users will get strong side effects with little subjective benefit, which is part of why the newer selective options have displaced it.
What are the risks & downsides of GHRP-6?
Downside contribution: 2.30 (safety risks weighted extra)
| Dimension | Weight | Score | Visual | Weighted |
|---|---|---|---|---|
| Safety | 30% | 3.0 | 0.900 | |
| Side effects | 15% | 3.6 | 0.540 | |
| Cost | 5% | 2.6 | 0.130 | |
| Effort | 5% | 3.2 | 0.160 | |
| Opportunity | 5% | 3.2 | 0.160 | |
| Dependency | 15% | 2.6 | 0.390 | |
| Reversibility | 25% | 1.8 | 0.450 | |
| Total | 2.730 | |||
| Harm subtotal × 1.4 | 3.192 | |||
| Opportunity subtotal × 1.0 | 0.450 | |||
| Combined downside | 3.642 | |||
| Baseline offset (constant) | −1.340 | |||
| Effective downside penalty | 2.302 |
Downside Rationale
The downside of GHRP-6 is dominated by a heavy, goal-defeating side-effect profile rather than acute danger. It has no documented catastrophic effect at standard doses, and it clears in hours, so anything that goes wrong corrects fast. The weight comes from the strongest appetite stimulation of the common peptides in this group, plus off-target cortisol, ACTH, prolactin, and water retention, and from a real opportunity cost: newer selective options do the same growth-hormone job with far fewer side effects. The grey-market supply adds an unregulated quality risk on top of the pharmacology. Dependency is low and reversibility is excellent, which keeps the total from climbing higher. The key thing to understand about GHRP-6's downside is that most of it is self-defeating rather than dangerous. The side effects do not threaten your life. They threaten the exact goal you bought the peptide for. Hunger fights fat loss, water retention masks the look you are chasing, and the off-target hormones are the opposite of what someone optimizing for performance wants. That is a different kind of bad than a toxic compound, and it is why the most exposed person here is not the unhealthy user but the lean one trying to get leaner.
Safety Risk (3.0/5.0): Safety risk is moderate, driven by metabolic and supply concerns rather than an intrinsic life-threatening effect. There is no documented catastrophic signal for GHRP-6 at standard doses. The real concerns are growth-hormone biology and what you are actually injecting. Raising growth hormone opposes insulin and can drift glucose and reduce insulin sensitivity as a class effect, per White 2009, and chronically elevated IGF-1 is the standard long-term cancer caution for anything that lifts this axis, so active cancer is an absolute contraindication. On top of the pharmacology, GHRP-6 has no FDA approval and is sold as a research chemical, so the product is unverified for purity and identity. None of this is acutely dangerous, but it is enough to land safety in the middle.
Side Effect Profile (3.6/5.0): Side effects are the defining drag of GHRP-6 and the heaviest of the growth-hormone-secretagogue group. The signature complaint is intense hunger, which is separate from growth hormone and shown in animals to occur without any growth-hormone change, per Locke 1995. On top of that, GHRP-6 raises cortisol, ACTH, and prolactin, per Arvat 1997, because it is less selective than newer peptides, per Raun 1998. Water retention and a fuller, puffier look are common too. Most of these are dose-dependent and fade fast, but the appetite effect in particular fights a fat-loss goal directly, which is why this dimension scores high.
Financial Cost (2.6/5.0): Cost is moderate and ongoing. GHRP-6 is cheap per vial as a research chemical, one of the lower-cost options in this group, but daily dosing plus the near-mandatory GHRH peptide plus IGF-1 testing pushes a real cycle toward a few hundred dollars a month. It is not expensive per dose; the recurring spend on an unproven stack is the relevant framing.
Time/Effort Burden (3.2/5.0): Effort is meaningful. GHRP-6 requires reconstitution with bacteriostatic water, subcutaneous injection one to three times daily in a fasted state, careful timing around food, cold storage, and site rotation. It is almost always stacked with a GHRH peptide such as CJC-1295 no-DAC, which adds a second draw, and the cycling practice adds planning. That is a real daily logistics load compared with an oral supplement.
Opportunity Cost (3.2/5.0): Opportunity cost is genuine and higher than for most peptides here, because better options exist for the same goal. Ipamorelin is the selective version that avoids most of the appetite and cortisol problem, per Raun 1998, and tesamorelin is an FDA-approved option with real human fat-loss data in its population. Money and effort spent on the older, side-effect-heavy GHRP-6 could go to those, or to the training, protein, and sleep basics that move the same goals with far more certainty. Choosing GHRP-6 specifically for body composition mostly buys you more side effects.
Dependency/Withdrawal (2.6/5.0): Dependency risk is low. GHRP-6 is functional only: it does not create a withdrawal syndrome, and the growth-hormone effect simply ceases once the peptide clears. The one real adaptation is receptor desensitization with continuous exposure, per Huhn 1993, which is why people cycle, but there is no documented addiction or rebound crash.
Reversibility (1.8/5.0): Reversibility is excellent for GHRP-6 and one of its genuine strengths. With an elimination half-life of about 2.5 hours, per Cabrales 2013, a bad reaction or unwanted side effect clears within hours, and stopping returns the growth-hormone axis to baseline without a taper. The appetite spike and water retention resolve quickly once you stop dosing, so there is no lasting change to undo.
Is GHRP-6 worth it?
GHRP-6 sits in caution because it pairs a real, fast, historically important mechanism with an empty human outcomes file and the heaviest side-effect load of its group. It is one of the original growth-hormone-releasing peptides and genuinely pivotal to the science, but for the growth-hormone-optimization goal it is the weakest practical choice. The growth-hormone rise is real, per Bowers 1990, but no trial shows it produces fat loss or muscle, and the strong appetite, separate from growth hormone, per Locke 1995, actively fights a cutting goal. If you specifically want the hunger for a hard bulk, it has a niche. For almost everyone else, a selective option does the same job with fewer downsides.
✅ Best for: Experienced users running a hard mass or bulking phase who actively want the appetite boost to eat in a surplus, the one place the hunger is a feature instead of a bug. People curious about the oldest growth-hormone-releasing peptide and its place in the discovery of ghrelin. Users who already stack a GHRH peptide and want to compare the older option directly. Anyone who can source verified material with a certificate of analysis and will monitor IGF-1 and glucose. People who understand they are running an unproven, grey-market research chemical and accept that.
❌ Avoid if: You have a fat-loss goal, because the strong appetite works directly against eating less. You have active or hormone-sensitive cancer, since growth-hormone and IGF-1 signaling can promote proliferation. You are pregnant or breastfeeding, with no safety data. You have diabetes or poor glucose control, because growth hormone opposes insulin, per White 2009. You compete in tested sport, since growth-hormone-releasing peptides are banned at all times under WADA category S2. You want the cleanest option, in which case ipamorelin avoids most of the appetite and cortisol effect. You cannot verify source quality, since research-chemical contamination may exceed the intrinsic pharmacological risk.
What is GHRP-6 best for?
The overall BioHarmony score reflects the intervention's primary evidence profile. These subratings are independent assessments per use case.
| Use Case | Score | Summary |
|---|---|---|
| ○ Body Composition / Fat Loss Primary | 3.8 | Body composition is the headline use case but it rests on physiology, not human outcome data. GHRP-6 reliably raises growth hormone in people, per Bowers 1990, and the GHRH plus GHRP combination is one of the most potent stimuli available, per Haijma 2005. No trial measures fat or lean mass for this peptide, and the strong appetite effect, shown to be separate from growth hormone in animals, per Locke 1995, actively works against a cutting goal. The score reflects a real mechanism with the highest risk of self-sabotage of any peptide in this group. |
| ○ Muscle Growth / Hypertrophy Primary | 3.0 | No human muscle-growth trial exists for GHRP-6. The growth-hormone pulse it produces is real but far smaller than exogenous growth hormone, per Jaffe 1993, and nothing has been measured for hypertrophy in people. |
| ○ Cardiovascular | 3.0 | Cardiovascular is the one place GHRP-6 has a distinct research story, but it is preclinical. A second receptor, CD36, mediates a cytoprotective heart effect, per Bodart 2002, and GHRP-6 reduced oxidant damage and myocardial necrosis in animal infarct models, per Berlanga 2007. This is a different indication from growth-hormone optimization, it is all animal and cell work, and no human cardioprotection trial exists. The score credits a genuine and well-cited mechanism while making clear it is preclinical and not a reason to use GHRP-6 for body composition. |
Frequently Asked Questions
What is GHRP-6 and how does it work?
GHRP-6 is a synthetic six-amino-acid peptide that activates the ghrelin receptor on your pituitary to release a short pulse of your own growth hormone, per Bowers 1990. It is one of the original peptides in this class and historically pivotal: it was the research tool used to clone that receptor, per Howard 1996, which then led scientists to discover ghrelin itself, per Kojima 1999. So a lab peptide reverse-engineered an entire hormone system, which is its strongest claim to fame.
How much GHRP-6 do people take, and how is it stacked?
Community protocols run 100 to 300 mcg subcutaneously, 1 to 3 times daily, fasted, often with a pre-sleep dose. These are not approved doses. The response saturates near 1 mcg per kilogram, so larger single doses mostly add side effects, per Huhn 1993. It is almost always stacked with a GHRH peptide to exploit a documented synergy, per Leal-Cerro 1995. People cycle on and off because continuous exposure blunts the response.
Why does GHRP-6 make you so hungry?
GHRP-6 causes intense hunger because it activates ghrelin-receptor appetite centers in the brain, and that effect is separate from growth hormone. In animals, GHRP-6 triggered eating without changing growth-hormone levels, per Locke 1995. Users report strong hunger within about 20 to 60 minutes, the heaviest of the common peptides in this group. That makes it useful for eating during a hard bulk but counterproductive for fat loss. If hunger is a problem, a selective option like ipamorelin avoids most of it.
Does GHRP-6 actually work for fat loss and muscle?
There are no human outcome trials showing GHRP-6 changes fat mass, lean mass, or strength. The human evidence is acute growth-hormone response and diagnostic testing, where GHRP-6 reliably raises growth hormone and is even used to provoke it for diagnosis, per Haijma 2005. The body-composition expectation is an extrapolation from growth-hormone physiology, not from GHRP-6 trials. If you want a better-evidenced path, tesamorelin has actual human fat-loss data in its approved population.
GHRP-6 vs ipamorelin: which is better?
Ipamorelin is usually the better choice for growth-hormone optimization. Both raise growth hormone with no outcome trials, so the upside is similar, but the downside is very different. Ipamorelin was defined as the first selective secretagogue precisely because it avoids the cortisol and ACTH rise, per Raun 1998, and it causes far less appetite. GHRP-6 is the older, least selective option, so most people now run ipamorelin to escape the hunger and off-target hormones.
What is the GHRP-6 heart and cardioprotection research?
GHRP-6 has a genuine cardioprotection research story, but it is preclinical. Beyond the growth-hormone receptor, GHRP-6 binds a second receptor, CD36, that drives a protective program in heart tissue, per Bodart 2002, and it reduced oxidant damage and myocardial necrosis in animal infarct models, per Berlanga 2007. This is all animal and cell work, it is a different indication from growth-hormone optimization, and no human cardioprotection trial exists. Treat it as interesting science, not a reason to use GHRP-6.
Is GHRP-6 safe and what are the side effects?
GHRP-6 has no documented catastrophic signal at standard doses, but it has the heaviest side-effect load of the common peptides in this group. The main complaints are strong appetite, per Locke 1995, plus cortisol, ACTH, and prolactin elevation, per Arvat 1997, and water retention. Effects clear fast since it leaves the body in hours, per Cabrales 2013. The bigger practical risk is buying an unverified research chemical.
Who should avoid GHRP-6?
Anyone with active or hormone-sensitive cancer, diabetes or poor glucose control, or pregnancy should avoid GHRP-6, since growth-hormone and IGF-1 stimulation can worsen those conditions, per White 2009. Competitive athletes must avoid it too, because it is banned at all times under WADA category S2. Anyone with a fat-loss goal should also skip it, because the strong appetite, shown separate from growth hormone, per Locke 1995, works directly against eating less.
How fast does GHRP-6 work?
The growth-hormone rise from GHRP-6 is fast, happening within minutes of a subcutaneous dose, with an elimination half-life of about 2.5 hours, per Cabrales 2013. The hunger usually hits within about 20 to 60 minutes. Subjective effects like deeper sleep appear within days, while any body-composition change would take months and is not documented in trials. Because the effect is transient, growth hormone returns to baseline once the peptide clears, per Jaffe 1993.
What could change GHRP-6's score?
BioHarmony scores are living assessments. New research, regulatory changes, or personal context can shift the score up or down. These are the most likely scenarios that would change this intervention's rating.
The fastest path up is genuine human outcome data, and the fastest path down is a confirmed safety signal or evidence that the side effects make it strictly worse than the selective options. A single positive human trial in body composition would lift Efficacy and Evidence together. Because the current score rests on solid acute pharmacology but an empty outcomes file, real outcome data in either direction would move it more than usual. Side-effect findings would mostly confirm the existing high mark rather than change the tier. The realistic outlook is that none of these moves is likely soon, because GHRP-6 has had the least modern clinical development of the peptides in this family and most current research effort sits in the preclinical heart and brain work rather than in human body-composition trials. The selective newer options also keep absorbing the attention and the budget. So the most probable future is that GHRP-6 stays where it is, a historically important tool that newer peptides have quietly outclassed for the goal people actually have.
| Scenario | Dimension shifts | New Score |
|---|---|---|
| A human trial shows real body-composition benefit | Efficacy 2.8 to 3.8, Evidence 2.5 to 3.3 | 4.8 / 10 ⚖️ Neutral |
| A head-to-head shows GHRP-6 matches ipamorelin with manageable sides | Side effects 3.6 to 2.8, Breadth 2.8 to 3.2 | 4.6 / 10 ⚖️ Neutral |
| Human cardioprotection data confirms a distinct clinical use | Breadth 2.8 to 3.6, Evidence 2.5 to 3.0 | 4.6 / 10 ⚖️ Neutral |
| A credible cancer or metabolic harm signal emerges | Safety 3.0 to 4.2, Evidence 2.5 to 2.2 | 3.9 / 10 ⚠️ Caution |
| Independent testing keeps finding mislabeled or contaminated product | Safety 3.0 to 3.6, Bioindividuality 2.8 to 2.4 | 4.1 / 10 ⚠️ Caution |
| Trials confirm the selective options are strictly better | Opportunity 3.2 to 4.0, Side effects 3.6 to 4.0 | 4.3 / 10 ⚠️ Caution |
A synthetic research peptide reverse-engineered an entire hormone system. GHRP-6 was the tool that helped clone the ghrelin receptor, which then led scientists to ghrelin itself. Kojima 1999
The appetite effect is separate from growth hormone. In animals, GHRP-6 triggered eating without any change in growth-hormone levels, which is exactly why the hunger is so hard to dose around. Locke 1995
Key Evidence Sources
- Bowers 1990, J Clin Endocrinol Metab: GHRP-6 stimulates growth-hormone release in normal men and acts synergistically with GHRH.. Seminal in-man study; GHRP-6 is a bona fide human growth-hormone secretagogue with GHRH synergy
- Howard 1996, Science: cloning and characterization of the growth hormone secretagogue receptor and its role in growth-hormone release.. Receptor cloning study; GHRP-6 was the pharmacological tool used to characterize the GHS receptor
- Kojima 1999, Nature: isolation of ghrelin, the endogenous ligand of the growth hormone secretagogue receptor.. Ghrelin discovery; the GHRP receptor search led to this endogenous hormone (related compound, mechanistic context)
- Locke 1995, Life Sci: intracerebroventricular GHRP-6 stimulates eating without affecting plasma growth-hormone responses in rats.. Animal study showing the appetite effect is dissociated from growth hormone, the basis of the GHRP-6 hunger problem
- Haijma 2005, Eur J Endocrinol: the GHRH plus GHRP-6 test as a diagnostic growth-hormone provocation in elderly and obese men.. Diagnostic study; the most established human use of GHRP-6 is provocation testing, not therapy
- Cabrales 2013, Eur J Pharm Sci: human pharmacokinetics of GHRP-6, distribution half-life about 7.6 minutes and elimination about 2.5 hours.. Human PK study quantifying the short, transient exposure profile
- Huhn 1993, J Clin Endocrinol Metab: a 24-hour GHRP infusion enhances pulsatile growth hormone but attenuates the response to a later bolus.. Human study showing desensitization with continuous exposure, the basis for pulsatile dosing and cycling
- Jaffe 1993, J Clin Endocrinol Metab: a prolonged GHRP infusion enhances pulsatile growth-hormone secretion in normal men.. Human study confirming the growth-hormone effect is transient and pulse-based
- Leal-Cerro 1995, Eur J Endocrinol: GHRH plus GHRP-6 combination growth-hormone response in adults with growth-hormone deficiency.. Human study reproducing the GHRH plus GHRP synergy in a deficient population, the rationale for stacking
- Arvat 1997, Peptides: GHRPs stimulate growth hormone, prolactin, ACTH, and cortisol in man, showing cross-activity beyond growth hormone.. Human study establishing the cortisol, ACTH, and prolactin cross-activity of the GHRP class
- Raun 1998, Eur J Endocrinol: ipamorelin is described as the first selective growth hormone secretagogue, releasing growth hormone without the cortisol rise.. Selectivity benchmark; frames the older GHRP-6 as the less-selective comparator (related compound, mechanistic context)
- Bodart 2002, Circ Res: CD36 mediates the cardiovascular action of growth-hormone-releasing peptides in the heart.. Preclinical receptor study; the basis of the cardioprotection research direction, a different indication
- Berlanga 2007, Clin Sci: GHRP-6 prevents oxidant cytotoxicity and reduces myocardial necrosis in a model of acute myocardial infarction.. Preclinical cytoprotection study in animals; not human outcome evidence
- White 2009, J Clin Endocrinol Metab: an oral growth-hormone secretagogue raised growth hormone and IGF-1 in older adults alongside reduced insulin sensitivity.. Class-level human outcome and metabolic-liability data (related compound, mechanistic context); not GHRP-6 specific
What does the evidence say about GHRP-6?
Evidence on this intervention is summarized across three complementary streams: contemporary clinical research, pre-RCT-era pharmacology and observational use, and the traditional medical systems that documented it first. Convergence across streams signals higher confidence; divergence is surfaced honestly.
Modern Clinical Research
Confidence: Low
Citations: Bowers 1990, Cabrales 2013, Locke 1995, Haijma 2005, Arvat 1997, Raun 1998
What to Track If You Try This
These are the data points that matter most while running a 30-day Experiment with this intervention.
How to read this section
- Pre
- Test or score before starting the protocol. Anchors a baseline.
- During
- Track while running the protocol so you can see if anything is changing.
- Post
- Re-test after a full cycle to confirm the change held.
- Up
- The marker should rise. For most positive outcomes, that is a good sign.
- Down
- The marker should fall. For most positive outcomes, that is a good sign.
- Stable
- The marker should hold steady. Big swings in either direction are a yellow flag.
- Watch
- Direction depends on dose, timing, and your baseline. Pay close attention to the trend.
- N/A
- No expected direction. The entry is there to anchor a baseline reading.
- Primary
- The Pulse dimension most likely to shift. Track this first.
- Secondary
- Also relevant, but a smaller or less consistent shift. Track if Primary is unclear.
Bloodwork to Order
Open These Markers In Your Dashboard
- IGF 1 Pre | Expected Watch During | Expected Up
- Fasting Glucose During | Expected Watch
Pulse Dimensions to Watch
- Body During | Expected Watch | Primary
- Sleep During | Expected Up | Secondary
- Energy During | Expected Up | Tertiary
Subjective Signals (Daily Voice Card)
- Hunger intensity in the hour after injection Scale 1-5 | During | Expected Watch
- Water retention, facial puffiness, or a fuller look Scale 1-5 | During | Expected Watch
Red Flags: Stop and Consult
- Hunger so strong it derails your eating plan: reduce dose or switch to a more selective option.
- Rising fasting glucose or new insulin-resistance signs: stop and consult a clinician, especially with diabetes.
- Any active or suspected cancer: do not use, since growth-hormone and IGF-1 stimulation is contraindicated.
- Signs of low mood, low libido, or breast tenderness: possible cortisol or prolactin effect, reduce dose or stop.
Other interventions for Body Composition
See all ratings →📊 How BioHarmony scoring works
BioHarmony translates a weighted expected-value calculation into a reader-facing 0–10 score. Tier bands: Skip 0–3.6, Caution 3.7–4.7, Neutral 4.8–5.7, Worth Trying 5.8–6.9, Strong Recommend 7.0–7.9, Top-tier 8.0+.
Harm-type downsides (safety risk, side effects, reversibility, dependency) carry a 1.4× precautionary multiplier. Harm weighs more than benefit. Opportunity-type downsides (financial cost, time/effort, opportunity cost) are subtracted at face value.
Use case subratings are independent assessments of how well the intervention addresses specific health goals. They are not components of the overall score. Each subrating reflects the scorer's judgment based on use-case-specific evidence, safety, and effect sizes.
Every dimension is evaluated on a 1–5 scale, and the baseline (1) is subtracted before weighting. A perfect intervention with zero downsides contributes zero penalty rather than a residual floor, so top-tier scores are actually reachable.
EV = Upside − Downside
EV = 1.665 − 2.302 = -0.637
Formula v0.5 maps EV = 0 to score 5.0. Above neutral, 1 EV point equals 1 score point. Below neutral, 1 EV point equals about 0.71 score points, so EV = −7 reaches 0.0 while EV = +5 reaches 10.0. Both sides use the full 5-point half-scale.
Score = 5 + (-0.637 / 7) × 5 = 4.5 / 10
